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Background: Large deletions within CFTR have been estimated to constitute 1–2% pathogenic alleles, but the occurrence could be much higher in
classical cystic ﬁbrosis (CF) patients with one mutation detectable by the routine screening/sequencing work-up. Currently, evaluation of major
CFTR rearrangements is not included in the mutation analysis for the reproductive partner of a CF patient/carrier.
Methods: Exon sequencing andMultiplex Ligation-dependent Ampliﬁcation (MLPA) analyses were used to make a molecular diagnosis of two unrelated
CF patients. Long PCR, restriction mapping, cloning, and hot start sequencing were employed to accurately annotate the rearrangement junctions.
Results: Both patients had a heterozygous single amino acid deletion mutation identiﬁed by sequencing, and a heterozygous deletion of CFTR
exons 17a and 17b detected by MLPA. Molecular characterization of the rearrangement breakpoints indicated that the two patients had an identical
complex c.2988+1616_c.3367+356del3796ins62 change, ﬂanked by a pair of perfectly inverted repeats of 32 nucleotides.
Conclusions: The c.2988+1616_c.3367+356del3796ins62 complex rearrangement is a recurrent mutation from patients of different ethnic
backgrounds. This mutation can be detected through a simple PCR based analysis.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR; Rearrangement; MLPA; Carrier screening1. Introduction
More than 1800 sequence variations, including pathogenic
mutations, variants of uncertain significance, and benign variants,
have been identified in the cystic fibrosis transmembrane
conductance regulator gene (CFTR) gene. A vast majority of the
pathogenic mutations for cystic fibrosis (CF) are point mutations or
small insertion/deletions (http://www.genet.sickkids.on.ca/cftr/
app). A three-base pair in-frame deletion, c.1521_1523delCTT
(p.F508del), accounts for 30–70% mutant alleles depending on
ethnic background. Gross rearrangements, including large⁎ Corresponding author at: Department of Molecular and Human Genetics,
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to constitute 1–2% of CFTR pathogenic alleles [1]. A number of
recent publications indicated that the frequency of CFTR major
rearrangements in classical CF patients with only one mutation
identified by common mutation screening and/or exon sequencing
was 11–60% [1–4]. Under such a scenario, the greater the clinical
suspicion of CF, the higher the likelihood that the second mutation
is a deletion.
We report here a 3.8-kb CFTR deletion, detected by MLPA, in
two unrelated CF patients of different ethnicity in our laboratory.
Through the analysis of the deletion breakpoint region it was
discovered that this rearrangement not only contained a deletion
that completely removes exons 17a and 17b, but also a 62-bp
insertion (c.2988+1616_c.3367+356del3796ins62). Our se-
quence data suggest that the derivation of this complex mutation
involves duplication, deletion, and inversion. The CFTR exonby Elsevier B.V. All rights reserved.
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breakpoints for the complex rearrangements in this region, such as
the one identified in our patients, have been rarely characterized.
Based on the characterized breakpoints, we were able to develop a
duplex PCR-based method for rapid detection/confirmation of
deletion/insertion mutations identified in our patients.
2. Patients and methods
2.1. Patients
Patient I was a one month old Hispanic male newborn. During




Fig. 1. MLPA detected a heterozygous deletion of CFTR exons 17a and 17b in both
heterozygous p.I507del (in patient I) or p.F508del (in patient II) mutation.CFTR mutation screening. The mother was positive for a
heterozygous p.I507del mutation while the father tested negative
for the common mutations. The patient reportedly had an
abnormal CF newborn screening with elevated immunoreactive
trypsinogen (IRT) and one copy of the p.I507del mutation.
Subsequent sweat chloride testing was positive (108 mEq/L) and
fecal elastase 1 test was b15microg/g (normal N200microg/g),
indicating pancreatic insufficiency. There was no family history
of CF or other pulmonary diseases.
Patient II was a 24-year old pregnant woman with Caucasian,
Hispanic, and African American background. She was diagnosed
with CF at three months of age with sweat chloride level
81 mEq/L. Her current clinical manifestations include mildn 17b p.F508del 
 
n 17b p.F507del 
 
patient I (top) and patient II (bottom). The MLPA F508del probe also detected a
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sensitive Staphylococcus aureus, pancreatic insufficiency, and
CF-related diabetes mellitus. The patient's brother was also
affected and infertile. No prior genetic testing was conducted
for this patient.2.2. CFTR mutation analysis
Sanger sequencing for the 27 coding exons of CFTR
(NM_000492.3) was performed following standard protocols
using the BigDye Terminator Cycle Sequencing kit (version 3.1)B
A
Fig. 2. Structure of the rearrangement breakpoints. (A) Location of the breakpoints
62 bp inserted sequence is highly homologous to the part of the upstream sequences
rearranged region is flanked by a pair of perfectly inverted repeats of 32 bp. The start
The nucleotide sequence alignment shows that I and II (reverse-complemented) areand analyzed on an ABI3730XL automated DNA sequencer
with Sequencing Analysis Software v5.1.1 (Applied Biosystems,
Foster City, CA, USA). Deletion/duplication analysis was
conducted by using the MLPA kit (SALSA® P091-C1 CFTR,
MRC-Holland, Amersterdam, The Netherlands) following the
manufacture's protocol (Fig. 1).2.3. CFTR rearrangement molecular characterization
Primer pair (Fig. 2A) CFTR-del16F (5′‐CGGGTAGAGAA
CTGGCTCAC‐3′) and CFTR-del18R (5′‐AATGCGGATGTT, primers, and the previously reported c.3121-977_c.3499-248del2515 [8]. The
(c.2988+1586 to c.2988+1647), but inserted in an inverted orientation. (B) The
and end of the 32 bp repeats (blue arrows) are denoted by vertical dashed lines.
highly homologous.
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WI, USA) were used to amplify a ~4.4 kb fragment containing
the deletion junctions. Restriction mapping (PstI and EcoRI) was
used to narrow down the breakpoints and a new pair of primers
CFdel17a+b-intF (5′‐CCCAAGTGAACTTTGGCATT‐3′) and
CFdel17a+b-intR (5′‐CTCTCTTGTGCCTGTTGCAG) was uti-
lized to amplify a shorter fragment (1.3 kb) encompassing the
breakpoints. The resultant PCR product was gel-purified and
cloned into a pCR®4-TOPO® vector (Invitrogen, Carlsbad, CA,
USA) for further sequence analysis.
Due to the presence of inverted repeats in the deletion junction
region, hot start sequencing was performed to open up the
secondary hairpin structure [5]. The sequencing primers are
CFdel17a+b-intF2 (5′‐ATCTTGGCTGACTGCAACCT‐3′) and
CFdel17a+b-intR2 (5′‐AATGCGGATGTTTCATTTCC‐5′).
2.4. Development of a PCR-based method to detect the deletion
Primers CFdel17a+b-intF and CFdel17a+b-intR2 were
used to amplify the deletion junction using the following
cycling condition: 94 °C 2 min, then 35 cycles for 92 °C 15 s,
62 °C 30 s, 72 °C 1 min, and a final extension step at 72 °C for
5 min. Another primer pair used to amplify CFTR exon 11
(CFTR_12F 5′-CAACTGTGGTTAAAGCAATAGTGTGA‐3′
and CFTR_12R 5′‐TGTGATTCTTAACCCACTAGCCATA‐
3′) was multiplexed in the reaction as an internal control for the
success of PCR. The Platinum® Taq Polymerase (Life Technol-
ogies, Grand Island, NY, USA) was employed in the duplex
PCR.
3. Results
3.1. CFTR mutations in the two patients
CFTR sequence analysis confirmed the presence of a
heterozygous p.I507del mutation in patient I and detected a
heterozygous p.F508del mutation in patient II. MLPA analysis
revealed that both patients harbored a heterozygous deletion
encompassing exons 17a and 17b. In addition, the p.I507del orPTI   PTII  NL1  NL2  NL3  NTC 
Fig. 3. A duplex PCR-based method for rapid detection/confirmation of the recurren
two patients described in this study that had the c.2988+1616_c.3367+356del3796in
stands for non-template control for the reaction. Pos is the recombinant pCR®4-TOP
and CFdel17a+b-intR.p.F508del mutation was also detected by the MLPA F508del
probe (Fig. 1).
3.2. Molecular characterization of the rearrangement
Both patients had a ~3.8 kb indel involving a deletion of
3796 bp containing exons 17a and 17b, and an insertion of
62 bp (c.2988+1616_c.3367+356del3796ins62) (Fig. 2A).
This inserted sequence is highly homologous to the upstream
sequences (c.2988+1586 to c.2988+1647), but is inserted in
an inverted orientation. As a result, the rearranged region is
flanked by a pair of perfectly inverted repeats of 32 bp
(Fig. 2B).
3.3. Duplex PCR for detection/confirmation of the recurrent
rearrangement
Primer pair CFdel17a+b-intF and CFdel17a+b-intR2 is
expected to yield a 694 bp product in the presence of this
deletion, whereas the region of 4438 bp corresponding to
the wild-type allele is not expected to be amplified using
the designated thermocycling conditions. Control primers
CFTR_12F and CFTR_12R should generate a 393 bp band
containingCFTR exon 11. This duplex PCR assay was utilized to
test the 2 patients with this deletion and three normal individuals.
The results demonstrated that this system can quickly detect the
c.2988+1616_c.3367+356del3796ins62 rearrangement (Fig. 3).
The PCR assay is also highly reproducible since three
independent runs yielded identical results (data not shown).
3.4. Mutation frequency of the c.2988+1616_c.3367+
356del3796ins62 allele
Ninety patients with a possible or definite diagnosis of CF
were tested for CFTR gene deletion/duplication and full gene
sequencing. A total of 93 pathogenic alleles were identified
(93/180) and two unrelated patients were heterozygous for the
c.2988+1616_c.3367+356del3796ins62 rearrangement. The694 bp specific for the deletion
393 bp CFTR exon 11 control
 Unused primers
 Pos 
t c.2988+1616_c.3367+356del3796ins62 mutation. PTI and PTII stand for the
s62 mutation. NL1, NL2, and NL3 are three independent normal controls. NTC
O® plasmid that contained the ~1.3 kb fragment amplified by CFdel17a+b-intF
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~1/46 in our limited cohort.
4. Discussion
4.1. CFTR exon 17a–17b region is a hot spot for gene
rearrangements
Genomic rearrangements in CFTR have been associated with
diverse mutational mechanisms, including non-homologous
recombination, retrotranspositional-competent LINE-1 mediated
genetic instability [3], and serial replication slippage [6]. The
CFTR exon 17a–17b region is a hot spot for gene rearrangements
due to its repetitive homologous sequences [6–9]. However, the
breakpoints for the complicated rearrangements in this region
have been rarely characterized. When compared to published
CFTR large deletions exclusively involving exons 17a+17b, our
complicated 3.8 kb indel is different from the 2.5 kb simple de-
letion (c.3121-977_c.3499-248del2515) reported from a French
patient cohort [8], while is most likely identical to the deletion
detected in an African-American patient [2]. In the latter, primer
pairs CFTR-del16F and CFTR-del18R also yielded a ~4.4 kb
product. However, the precise rearrangement junctions were not
mapped, possibly due to the presence of the 32 bp inverted repeats
which posed challenges for sequencing. Duplication, deletion, and
inversion need to be evoked for the wild-type allele to evolve into
this complex structure.
Following the identification of the rearrangement breakpoints,
we developed a rapid, simple duplex PCR assay to detect
this recurrent c.2988+1616_c.3367+356del3796ins62 mutation.
This system is also expected to catch the previously reported
c.3121-977_c.3499-248del2515 deletion [8] (Fig. 2A). Therefore,
this PCR assay can potentially detect the majority of the deletions/
duplications falling within the covered region.
4.2. Pitfalls of carrier screening without duplication/deletion
analysis
Although reliable and high-throughput methods exist for
CFTR extended mutational search [10] and sequencing data
analysis [11], current CFTR mutation analysis of the reproductive
partner of a CF patient/carrier generally only includes screening
of the common mutations, and on rare occasions, sequencing
analysis of the entire coding sequences, but not testing for gross
rearrangements. The history of Patient I's family demonstrated thelimitations of prenatal CF carrier screening without inclusion of
deletion/duplication analysis. Because at least 1 in 50 CF carriers
harbors a deletion mutation and MLPA is a simple technique with
a fast turnaround time, we recommend that a comprehensive
CFTR mutation work-up, including deletion/duplication analysis,
be considered by the reproductive partners of known CF patients
or carriers.References
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